The Mesoblast Ltd (ASX: MSB) share price is in focus today after the company reported a 44% jump in Ryoncil net revenue to US$28 million and an 85% improvement in net operating cash spend for the first fiscal quarter.
Image source: Getty Images
What did Mesoblast report?
- Net revenue from Ryoncil sales rose 44% to US$28 million (Q1 FY25: US$19 million)
- Net operating cash spend improved 85% to just US$2.3 million (prior period: US$14.9 million)
- Strong cash position: US$99 million at 30 September 2026
- Record new patient starts in September after seasonal July/August slowdown
What else do investors need to know?
Mesoblast attributes its revenue growth and improved cash position to greater penetration and adoption of Ryoncil across 54 onboarded treatment sites. Ryoncil is the first and only FDA-approved mesenchymal stromal cell therapy for children under 12 with steroid-refractory acute graft-versus-host disease.
The company is also focusing on disciplined capital management to support its commercial manufacturing and late-stage clinical programs. All reported results are preliminary and subject to audit.
What's next for Mesoblast?
Looking ahead, Mesoblast plans to expand the reach of Ryoncil, further increasing adoption among eligible hospitals and clinics. The company is also progressing additional pipeline products targeting inflammatory diseases and is strengthening commercial partnerships overseas.
Disciplined capital use and investment in late-stage clinical trials remain priorities. Management is focused on building sustainable growth while maintaining strong cash reserves.
Mesoblast share price snapshot
Over the past 12 months, Mesoblast shares have declined 29%, trailing the S&P/ASX 200 Index (ASX: XJO), which has declined 2% over the same period.
